Citizens JMP reiterates Market Perform rating on CoreWeave stock

Citizens JMP maintained a Market Perform rating on CoreWeave (CRWV), citing the AI compute provider's high current valuation (52.6x EV/EBITDA) as already reflecting much of its growth potential, despite an 8% stock decline last week. This cautious outlook comes as CoreWeave plans a $6 billion AI data center investment and agreed to acquire Core Scientific for $9 billion in an all-stock transaction. While analysts like Mizuho and Needham acknowledge the strategic benefits of the acquisition, both firms downgraded CRWV to Neutral or Hold, respectively, due to persistent valuation concerns, highlighting a consensus that the stock's current price already incorporates significant future upside despite CoreWeave's technological leadership and expansion in the rapidly growing AI infrastructure market.

Analysis

A consensus of analyst caution is forming around CoreWeave (CRWV) due to its high valuation, despite a series of strategically positive announcements. While the company is expanding aggressively through a planned $6 billion AI data center investment and a $9 billion all-stock acquisition of Core Scientific, research firms are signaling that these developments are already priced into the stock. Citizens JMP's 'Market Perform' rating reflects this view, highlighting a steep EV/EBITDA multiple of 52.6x. This sentiment is echoed by both Mizuho and Needham, which downgraded CoreWeave to 'Neutral' and 'Hold' respectively, citing valuation concerns even as they acknowledged the strategic merits and potential synergies of the Core Scientific deal. The stock's recent 8% decline suggests the market is weighing these valuation headwinds against the company's strong execution, which includes its technological leadership as the first cloud provider to offer NVIDIA's Blackwell server instances.

Key Decisions for Investors

• Investors should exercise caution due to the stock's high valuation, as multiple analyst downgrades suggest that significant future growth is already priced in at an EV/EBITDA multiple of 52.6x.
• The successful integration of the $9 billion Core Scientific acquisition is now a critical performance indicator; monitor future earnings reports for evidence of the projected cost synergies and financing flexibility.
• Given the recent 8% stock decline and cautious analyst sentiment, it may be prudent to await a more attractive entry point or signs of price stabilization before establishing or increasing a position.